A Study of LY3214996 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-01

Study Completion Date

2019-09-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will involve a single dose of 14C radiolabelled LY3214996. This means that a radioactive substance, C14, will be incorporated into the study drug. The purposes are to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine and feces. The study will last up to six weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiolabeled Study of CC-122 in Healthy Subjects

NCT02234999

Healthy Volunteers

COMPLETED PHASE1

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104

NCT01448395

Healthy

COMPLETED PHASE1

Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Pitolisant in Healthy Male Volunteers

NCT02929342

Healthy Volunteers

COMPLETED PHASE1

A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

NCT03864601

Healthy

COMPLETED PHASE1

A Single-center Study to Investigate How Quickly and to What Extent a Radioactive Dose of RO5285119 is Absorbed, Metabolized and Eliminated From the Body of Healthy Male Volunteers

NCT02179866

Healthy Volunteer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3214996 + [14C]-LY3214996

A single dose of LY3214996 and \[14C\]-LY3214996 administered orally.

Group Type EXPERIMENTAL

LY3214996

Intervention Type DRUG

Administered orally

[14C]-LY3214996

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3214996

Administered orally

Intervention Type DRUG

[14C]-LY3214996

Administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Overtly health males
* Body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive

Exclusion Criteria

* Females
* Male participants sexually active with a pregnant partner
* Are currently enrolled in a clinical study or have participated, within the last 30 days, in a clinical study
* Have participated in a radiolabeled drug study within the previous 4 months
* Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
* Have a history of Gilbert's syndrome
* Have history or presence of psychiatric disorders
* Show evidence of human immunodeficiency virus (HIV) infection
* Show evidence of hepatitis C
* Show evidence of hepatitis B

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes